Cytokinetics Inc (CYTK)
Return on equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | -526,244 | -388,955 | -215,314 | -127,290 | -121,692 |
| Total stockholders’ equity | US$ in thousands | -386,323 | -107,900 | 243,863 | 113,383 | -10,937 |
| ROE | — | — | -88.29% | -112.27% | — |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $-526,244K ÷ $-386,323K
= —
The return on equity (ROE) for Cytokinetics Inc has shown a significant improvement over the years. In 2021, the ROE was -88.29%, indicating a negative return on equity, which improved to -112.27% in 2020. The negative ROE suggests that the company's net income was not sufficient to generate positive returns for shareholders' equity.
However, it is important to note that the ROE data for 2023 and 2019 is not available, making it difficult to provide a complete trend analysis. It would be important to investigate the reasons behind the negative ROE figures in 2020 and 2021, such as high levels of debt, ineffective cost management, or operational inefficiencies.
Overall, the negative ROE figures for Cytokinetics Inc in recent years indicate that the company may be facing challenges in generating profits relative to its shareholders' equity. Further analysis and examination of the company's financial statements and performance indicators would be necessary to fully understand the factors contributing to the ROE trends.
Peer comparison
Dec 31, 2023